Introduction: Stability assessment is a core subject for B. Pharm students, covering regulatory guidelines and practical testing needed to establish product shelf life and ensure product quality. This overview emphasizes regulations related to stability assessment, including ICH guidelines (Q1A–Q1F), ICH Q1B photostability, USP requirements, regional regulatory expectations, stability protocols, accelerated and long-term stability testing, storage conditions, and stability-indicating analytical methods. Focus areas include data integrity, batch selection, bracketing and matrixing, forced degradation, statistical evaluation, and documentation required for registration and post-approval changes. Practice with real-world case examples and reporting templates strengthens competency. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which ICH guideline primarily describes the stability testing requirements for new drug substances and products?
- ICH Q1A(R2)
- ICH Q3A
- ICH Q5C
- ICH Q8
Correct Answer: ICH Q1A(R2)
Q2. What is the primary purpose of forced degradation (stress testing) in stability assessment?
- To determine manufacturing yield
- To identify likely degradation pathways and develop stability-indicating methods
- To reduce packaging costs
- To establish clinical efficacy
Correct Answer: To identify likely degradation pathways and develop stability-indicating methods
Q3. Which guideline specifically provides recommendations for photostability testing of new drug substances and products?
- ICH Q1A
- ICH Q3B
- ICH Q1B
- ICH Q5C
Correct Answer: ICH Q1B
Q4. In stability studies, what does “accelerated stability testing” aim to achieve?
- Assess stability under exaggerated conditions to predict long-term behavior
- Replace long-term studies entirely
- Test only packaging robustness
- Evaluate patient acceptability
Correct Answer: Assess stability under exaggerated conditions to predict long-term behavior
Q5. Which storage condition is commonly used as an accelerated condition for stability studies in temperate (zone II) regions?
- 5°C ±3°C
- 25°C/60% RH
- 40°C/75% RH
- 0°C ±5°C
Correct Answer: 40°C/75% RH
Q6. What is the meaning of “bracketing” in stability study design?
- Testing all strengths and container sizes at all time points
- Testing only the extremes (e.g., highest and lowest strengths) to represent intermediate strengths
- Testing only the smallest container size
- Testing at subzero temperatures
Correct Answer: Testing only the extremes (e.g., highest and lowest strengths) to represent intermediate strengths
Q7. What does “matrixing” allow in a stability study?
- Testing a subset of time points and strengths for each batch to reduce testing burden
- Using different analytical methods for each time point
- Replacing long-term data with accelerated data
- Testing only in-use stability
Correct Answer: Testing a subset of time points and strengths for each batch to reduce testing burden
Q8. Which parameter is most critical when declaring the shelf life of a drug product from stability data?
- Color of the label
- Retention of potency and acceptable impurity limits over time
- Manufacturing throughput
- Marketing exclusivity
Correct Answer: Retention of potency and acceptable impurity limits over time
Q9. According to regulatory guidance, which batches are typically recommended for stability studies submitted in a marketing application?
- Stability batches from pilot-scale only
- Three primary batches from production scale manufactured from different lots of API
- Only the first manufactured batch
- Any single laboratory batch
Correct Answer: Three primary batches from production scale manufactured from different lots of API
Q10. What is the role of a stability-indicating method?
- To improve product taste
- To separate and quantify the drug substance in presence of degradation products
- To determine dissolution alone
- To monitor environmental conditions in the lab
Correct Answer: To separate and quantify the drug substance in presence of degradation products
Q11. Which of the following is a common acceptance criterion for assay in stability studies?
- Assay must remain within the approved specification limits throughout shelf life
- Assay can decrease by any amount if impurities are low
- Assay only needs to be checked at time zero
- Assay does not need specification if impurities are monitored
Correct Answer: Assay must remain within the approved specification limits throughout shelf life
Q12. What regulatory document describes handling of post-approval changes impacting stability?
- ICH Q1E
- ICH Q7
- ICH M4
- ICH Q3A
Correct Answer: ICH Q1E
Q13. In stability protocols, why is sample storage condition monitoring important?
- To ensure samples are exposed to correct, documented conditions for valid data
- To reduce sample inventory
- To allow flexible storage by testers
- To determine color changes only
Correct Answer: To ensure samples are exposed to correct, documented conditions for valid data
Q14. Which factor is NOT typically evaluated in forced degradation studies?
- P H stress
- Oxidative stress
- Microbial contamination stress
- Thermal and photolytic stress
Correct Answer: Microbial contamination stress
Q15. For a new solid oral dosage form intended for global distribution, which climate zone conditions are considered for long-term stability testing?
- Only zone I conditions
- Conditions representative of intended markets; often zone II or zone IV depending on distribution
- Only refrigerated conditions
- Only at 0% RH
Correct Answer: Conditions representative of intended markets; often zone II or zone IV depending on distribution
Q16. What is the significance of “commitment batches” in regulatory submissions?
- They are smaller batches not used for stability
- They are additional batches committed to be tested post-approval to support shelf life claims
- They replace primary batches in the dossier
- They are used only for bioequivalence
Correct Answer: They are additional batches committed to be tested post-approval to support shelf life claims
Q17. Which regulatory expectation applies to analytical method validation for stability testing?
- Methods need not be validated if stability looks good
- Stability-indicating methods must be validated for specificity, precision, accuracy, linearity, and robustness
- Only precision is required
- Validation is only required for impurities
Correct Answer: Stability-indicating methods must be validated for specificity, precision, accuracy, linearity, and robustness
Q18. How is “retest period” different from “shelf life” in regulatory terms?
- Retest period applies to the drug product; shelf life applies to APIs only
- Retest period is for API reuse consideration; shelf life is for finished product availability to consumers
- They are interchangeable terms
- Retest period is always longer than shelf life
Correct Answer: Retest period is for API reuse consideration; shelf life is for finished product availability to consumers
Q19. Which documentation is essential to include in a stability report submitted to regulators?
- Only raw chromatograms without summaries
- Study protocol, complete raw data, summaries, statistical analysis, and conclusions
- Only the summary table of results
- Only photographs of samples
Correct Answer: Study protocol, complete raw data, summaries, statistical analysis, and conclusions
Q20. What is the recommended action when an out-of-specification (OOS) result occurs during stability testing?
- Immediately ignore and proceed
- Perform an investigation to identify root cause and impact on shelf life
- Destroy all remaining samples without analysis
- Report to marketing only
Correct Answer: Perform an investigation to identify root cause and impact on shelf life
Q21. Which analytical approach is preferred to demonstrate impurity profile changes over time?
- Visual inspection only
- Stability-indicating chromatographic methods with peak identification and mass balance considerations
- Use of fixed UV absorbance without separation
- Relying solely on p H measurements
Correct Answer: Stability-indicating chromatographic methods with peak identification and mass balance considerations
Q22. For photostability testing, what is a typical outcome regulators expect?
- No exposure to light is required
- Demonstration of the effect of light on active substance and finished product and suitable labeling if photolabile
- Only packaging should be tested, not product
- Light testing only at 5°C
Correct Answer: Demonstration of the effect of light on active substance and finished product and suitable labeling if photolabile
Q23. Which practice ensures data integrity in stability studies?
- Allowing manual undocumented data edits
- Maintaining audit trails, controlled access, and documented change control
- Keeping samples in unmonitored refrigerators
- Using verbal approvals only
Correct Answer: Maintaining audit trails, controlled access, and documented change control
Q24. When extrapolating shelf life from accelerated data, which approach is commonly used?
- Direct interpolation without justification
- Use of Arrhenius equation with appropriate justification and supporting long-term data when possible
- Assuming no degradation occurs
- Using photostability data only
Correct Answer: Use of Arrhenius equation with appropriate justification and supporting long-term data when possible
Q25. Which container-closure system aspect is critical in stability studies?
- Color of the cap only
- Interaction between product and container-closure that may affect stability, including extractables/leachables
- Only the size of the container
- Label font type
Correct Answer: Interaction between product and container-closure that may affect stability, including extractables/leachables
Q26. For biologics, which stability consideration is particularly emphasized by regulators?
- Simpler forced degradation than small molecules
- Stability of higher-order structure, potency, and immunogenicity risks over time
- No need for cold chain data
- Only chemical impurities matter
Correct Answer: Stability of higher-order structure, potency, and immunogenicity risks over time
Q27. What is the typical minimum duration of long-term stability studies for a new drug product at time of initial submission?
- 3 months
- 6 months
- 12 months or more depending on expected shelf life and guidelines
- 24 hours
Correct Answer: 12 months or more depending on expected shelf life and guidelines
Q28. How should accelerated results be treated if a product shows atypical degradation at accelerated conditions?
- Ignore and accept the shelf life
- Investigate mechanism, do not extrapolate shelf life without justification and additional data
- Automatically double the shelf life
- Only report accelerated results
Correct Answer: Investigate mechanism, do not extrapolate shelf life without justification and additional data
Q29. Which is an important regulatory expectation for stability sampling frequency?
- Sampling only at study end
- Sampling at time points justified to capture kinetics of degradation (e.g., 0, 3, 6, 9, 12 months, etc.)
- Random sampling without protocol
- Sampling solely based on convenience
Correct Answer: Sampling at time points justified to capture kinetics of degradation (e.g., 0, 3, 6, 9, 12 months, etc.)
Q30. Which statement best describes the regulatory view on in-use stability (open vial or reconstituted product)?
- In-use stability is never required
- In-use stability should be evaluated when relevant to recommended patient use and labeling
- In-use stability only matters for tablets
- In-use stability replaces long-term testing
Correct Answer: In-use stability should be evaluated when relevant to recommended patient use and labeling
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com